NON SMALL CELL LUNG CANCER NSCLC

This study tested whether adding tiragolumab to atezolizumab (both immunotherapy drugs) helps prevent non-small cell lung cancer from coming back after complete surgical removal and standard chemotherapy. 56 adults with stage IIB-IIIB PD-L1 positive tumors participated. The main …

This study tested whether a combination of two immunotherapy drugs (atezolizumab and tiragolumab) works better than the current standard drug (durvalumab) for people with stage III lung cancer that cannot be removed by surgery. Participants had already received chemotherapy and r…

This early-phase trial tested whether combining a special type of radiation (hypofractionated radiotherapy) with two immunotherapy drugs (MEDI4736 and tremelimumab) is safe and tolerable for people with advanced melanoma, lung, breast, or pancreatic cancer that has spread. The st…

This study tested an oral targeted drug called capmatinib in 36 Chinese adults with advanced non-small cell lung cancer that has a specific MET gene mutation (exon 14 skipping). The drug aims to block cancer growth by targeting this faulty gene. Researchers measured how many pati…

This study looked back at medical records of 70 adults in Argentina with a certain type of lung cancer (non-small cell lung cancer) that could be removed with surgery. All patients received a combination of the immunotherapy drug nivolumab and chemotherapy before their surgery. T…

This study tested a new drug combination (tiragolumab plus atezolizumab and chemotherapy) against a standard treatment (pembrolizumab plus chemotherapy) in 542 people with advanced non-squamous lung cancer who had not received prior treatment. The goal was to see if the new combo…

This study tested a new approach for people with advanced non-small cell lung cancer whose tumors have high levels of a protein called PD-L1. Instead of standard chemotherapy plus radiation, participants received immunotherapy (pembrolizumab) followed by a personalized 4-week cou…

This study tested a daily pill called osimertinib in 73 people with a specific type of lung cancer that had spread to the lining of the brain. The goal was to see if the drug could shrink these tumors and help people live longer. Participants took the medication once a day, and r…

This study looked at ways to improve PET/CT scans for people with non-small cell lung cancer. The goal was to see if changing how the images are taken and processed could make staging more accurate. Thirty adults took part, and the focus was on safety and image quality, not on tr…

This study tested whether small devices called Calypso beacons can help doctors track lung tumors during radiation treatment. 48 people with lung cancer took part. The beacons were placed near the tumor and sent signals to show its exact location while the patient held their brea…